Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Non-Current Assets (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Other Non-Current Assets for 7 consecutive years, with $538000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 55.2% to $538000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $538000.0, a 55.2% decrease, with the full-year FY2025 number at $538000.0, down 55.2% from a year prior.
  • Other Non-Current Assets was $538000.0 for Q4 2025 at Fulcrum Therapeutics, up from $9000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.0 million in Q4 2023 to a low of $9000.0 in Q3 2025.
  • A 5-year average of $1.1 million and a median of $1.1 million in 2021 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: surged 101.48% in 2022, then crashed 99.25% in 2025.
  • Fulcrum Therapeutics' Other Non-Current Assets stood at $542000.0 in 2021, then soared by 101.48% to $1.1 million in 2022, then surged by 84.16% to $2.0 million in 2023, then plummeted by 40.28% to $1.2 million in 2024, then plummeted by 55.2% to $538000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Other Non-Current Assets are $538000.0 (Q4 2025), $9000.0 (Q3 2025), and $1.2 million (Q2 2025).